Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Nektar TherapeuticsNASDAQ: NKTR

Change in Working Capital · Q2 FY2026 · quarter ended Jun 2026

Change in working capital growth accelerates

Q2 FY2026 change in working capital of $46.61M (cash outflow) rose 1201.7% year over year, ahead of the +464.0% change in trailing-twelve-month change in working capital. Sequentially, it rose 68450.0% from the prior quarter.

Context

  • Change in working capital amounted to 67.0% of revenue in FY2025, up 60.7 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1201.7% holds above the trailing-twelve-month pace of +464.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$46.61M+68450.0% QoQ
Last fiscal yearDec 2025
-$37.02M+493.3% YoY
LTMJun 2026
-$79.97M+464.0% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1201.7%——
1 year+493.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(37.02M) USD
Year-over-year change
-493.3%

Change in Working Capital vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +464.0% is the highest of 9, against a peer median of -54.7%.
  • Change in working capital amounts to 146.5% of revenue for NKTR, versus a peer median of 37.7%.
NKTR Competitors
Change in Working Capital for NKTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$87M USD-18.7%—74.4%
NKTRNektar TherapeuticsLTM Jun 2026$79.97M USD+464.0%—146.5%
CHRSCoherus Oncology, Inc.LTM Mar 2026$69.52M USD-189.0%-58.1%148.3%
IMCRImmunocore Holdings plcLTM Mar 2026$24.61M USD+2.6%-34.1%6.4%
MGNXMacroGenics, Inc.LTM Mar 2026$17.87M USD+67.2%+66.6%11.4%
IMTXImmatics N.V.LTM Mar 2026€14.05M EUR-90.7%—37.7%
IPHAInnate Pharma S.A.FY2025€10.21M EUR-126.1%-6.5%366.4%
ANLAdlai Nortye Ltd.LTM Jun 2024$7.18M USD——110.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$3.48M USD+328.3%+36.3%—
XNCRXencor, Inc.LTM Jun 2026$2.5M USD-91.4%-1.0%2.4%
CGENCompugen Ltd.LTM Dec 2025$0 USD—-1.2%0.0%
Peer median (excluding NKTR) —-54.7%-1.2%37.7%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Depreciation & Amortization14.15M13.03M7.82M4.39M(4.49M)
Deferred Income Tax8.02M2.71M(140K)00
Stock-Based Compensation94.67M57.32M33.39M21.61M12.65M
Change in Working Capital(23.08M)492K(19.8M)(6.24M)(37.02M)
Accounts Receivables12.4M16.51M4.78M(3.05M)0
Inventory(509K)(3.4M)699K497K0
Accounts Payables(11.69M)3.1M(2.88M)2.67M(625K)
Other Working Capital(23.27M)(15.72M)(22.39M)(6.36M)(36.39M)
Other Non-Cash Items17.41M(9.36M)62.19M(76.51M)(15.58M)
Operating Cash Flow(412.66M)(304.01M)(192.61M)(175.71M)(208.51M)
Capital Expenditures(14.99M)(5.68M)(865K)(1.47M)(171K)
Acquisitions (Net)(217.77M)13.2M065.39M(697K)
Purchases of Investments(960.69M)(467.91M)(511.7M)(261.71M)(285.01M)
Sales of Investments1.18B826.23M650.88M340.36M284.68M
Other Investing Activities217.77M01.25M00
Investing Cash Flow202.78M365.84M139.56M142.57M(1.2M)
Debt Repayment00000
Common Stock Issued33.24M758K30K30.12M180.57M
Common Stock Repurchased000(3M)0
Dividends Paid00000
Other Financing Activities3M750K015M0
Financing Cash Flow36.24M1.51M30K42.12M180.57M
Effect of Forex Changes(92K)(327K)62K(4K)6K
Net Change in Cash(173.74M)63.01M(52.95M)8.98M(29.14M)
Free Cash Flow(427.65M)(309.68M)(193.47M)(177.18M)(208.68M)

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.